Anthony J. Esposito, M.D.

An expert discusses the key unmet needs in current treatment approaches for idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF).

An expert discusses the treatment algorithm for patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF), along with insurance coverage for the available treatment options.

An expert discusses the gaps or outdated elements in the American Thoracic Society (ATS) guidelines that have been identified.

An expert discusses the main treatment recommendations of the American Thoracic Society (ATS) guidelines for managing with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF).

An expert discusses the management plan for patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF), highlighting approaches beyond pharmacotherapies.

An expert discusses the key side effects and contraindications associated with antifibrotic agents and how to monitor for and manage them.

An expert discusses how nintedanib and pirfenidone differ in their mechanisms of action and efficacy in treating idiopathic pulmonary fibrosis (IPF).

An expert discusses the current understanding of corticosteroids in managing pulmonary fibrosis and how it has evolved in recent years, and identifies specific patient populations for whom steroids may remain a viable treatment option.